Nubriveo 50 mg (brivaracetam)

Nubriveo is a brand name used in certain European markets, including Italy, for the antiepileptic drug brivaracetam. Originally developed by the Belgian biopharmaceutical giant UCB (Union Chimique Belge), it is indicated for the treatment of partial-onset seizures in patients with epilepsy. The brand represents a continuation of UCB's focus on neurology and central nervous system disorders.

The product is manufactured primarily in Belgium, at UCB's specialized pharmaceutical production facilities, although global distribution networks may involve secondary packaging sites. UCB remains the ultimate owner and developer of the drug, maintaining its headquarters in Brussels. In the Italian market, the product is distributed via UCB Pharma S.p.A., their local subsidiary.